JP2012525387A - ベンダムスチンの経口製剤 - Google Patents

ベンダムスチンの経口製剤 Download PDF

Info

Publication number
JP2012525387A
JP2012525387A JP2012508503A JP2012508503A JP2012525387A JP 2012525387 A JP2012525387 A JP 2012525387A JP 2012508503 A JP2012508503 A JP 2012508503A JP 2012508503 A JP2012508503 A JP 2012508503A JP 2012525387 A JP2012525387 A JP 2012525387A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
aqueous pharmaceutical
aqueous
polyethylene glycol
polyethylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012508503A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012525387A5 (enExample
Inventor
ワイ． ラベル、レイチェル
アール． パテル、ピユシュ
Original Assignee
セファロン、インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セファロン、インク． filed Critical セファロン、インク．
Publication of JP2012525387A publication Critical patent/JP2012525387A/ja
Publication of JP2012525387A5 publication Critical patent/JP2012525387A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2012508503A 2009-04-28 2010-04-01 ベンダムスチンの経口製剤 Pending JP2012525387A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17342309P 2009-04-28 2009-04-28
US61/173,423 2009-04-28
PCT/US2010/029578 WO2010126676A1 (en) 2009-04-28 2010-04-01 Oral formulations of bendamustine

Publications (2)

Publication Number Publication Date
JP2012525387A true JP2012525387A (ja) 2012-10-22
JP2012525387A5 JP2012525387A5 (enExample) 2013-05-16

Family

ID=42174186

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012508503A Pending JP2012525387A (ja) 2009-04-28 2010-04-01 ベンダムスチンの経口製剤

Country Status (7)

Country Link
US (1) US20120157505A1 (enExample)
EP (1) EP2424506A1 (enExample)
JP (1) JP2012525387A (enExample)
CN (1) CN102413816A (enExample)
CA (1) CA2760085A1 (enExample)
MX (1) MX2011011109A (enExample)
WO (1) WO2010126676A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013518130A (ja) * 2010-01-28 2013-05-20 イーグル・ファーマシューティカルズ・インコーポレーテッド ベンダムスチンの製剤
JP2013527207A (ja) * 2010-06-02 2013-06-27 アステラス ドイチュランド ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンダムスチンの経口投与形
JP2013527206A (ja) * 2010-06-02 2013-06-27 アステラス ドイチュランド ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンダムスチンの経口投与形及びその治療的使用
JP2016531138A (ja) * 2013-08-27 2016-10-06 ボウドウリス バシリオス ベンダムスチンの薬学的組成物
US9572887B2 (en) 2012-03-20 2017-02-21 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US9579384B2 (en) 2012-03-20 2017-02-28 Eagle Pharmaceuticals, Inc. Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
CN102125693A (zh) * 2011-01-25 2011-07-20 福建科瑞药业有限公司 一种盐酸噻加宾药物组合物及其制备方法
WO2013123227A1 (en) * 2012-02-14 2013-08-22 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
EP2641592A1 (en) * 2012-03-23 2013-09-25 Salmon Pharma GmbH Pharmaceutical formulation comprising bendamustine
US9320730B2 (en) * 2014-03-13 2016-04-26 Vasilios Voudouris Bendamustine solid dispersions and continuous infusion
CN105726472B (zh) * 2016-03-25 2019-12-13 南京康玻斯医药科技有限公司 苯达莫司汀药剂组合物及应用
WO2019068904A1 (en) 2017-10-05 2019-04-11 Tube Pharmaceuticals Gmbh ORAL ADMINISTRATION OF BENDAMUSTINE FORMULATIONS
CN110123747A (zh) * 2019-04-26 2019-08-16 嘉兴市爵拓科技有限公司 苯达莫司汀的制剂

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE159289C (enExample) * 1903-10-08 1905-03-16
JP2008519047A (ja) * 2004-11-05 2008-06-05 セフアロン・インコーポレーテツド 癌処置
JP2008526991A (ja) * 2005-01-14 2008-07-24 セフアロン・インコーポレーテツド ベンダムスチン製薬学的組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD159289A1 (de) * 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
DE10306724A1 (de) 2002-02-28 2003-09-18 G O T Therapeutics Gmbh Vesikuläre Verkapselung von Bendamustin
CN101219113A (zh) * 2008-01-28 2008-07-16 济南帅华医药科技有限公司 含苯达莫司汀的复方抗癌缓释注射剂

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE159289C (enExample) * 1903-10-08 1905-03-16
JP2008519047A (ja) * 2004-11-05 2008-06-05 セフアロン・インコーポレーテツド 癌処置
JP2008526991A (ja) * 2005-01-14 2008-07-24 セフアロン・インコーポレーテツド ベンダムスチン製薬学的組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6014015167; 日本医薬品添加物協会　編: 医薬品添加物事典 第１版, 1994, ｐｐ．９０，　１１９-１２１, 株式会社薬事日報社 *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10010533B2 (en) 2010-01-28 2018-07-03 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US12350257B2 (en) 2010-01-28 2025-07-08 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US9572796B2 (en) 2010-01-28 2017-02-21 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US11872214B2 (en) 2010-01-28 2024-01-16 Eagle Pharmaceuticals, Inc. Formulations of Bendamustine
US11844783B2 (en) 2010-01-28 2023-12-19 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US9572797B2 (en) 2010-01-28 2017-02-21 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US11103483B2 (en) 2010-01-28 2021-08-31 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
JP2013518130A (ja) * 2010-01-28 2013-05-20 イーグル・ファーマシューティカルズ・インコーポレーテッド ベンダムスチンの製剤
JP2013527207A (ja) * 2010-06-02 2013-06-27 アステラス ドイチュランド ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンダムスチンの経口投与形
JP2013527206A (ja) * 2010-06-02 2013-06-27 アステラス ドイチュランド ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンダムスチンの経口投与形及びその治療的使用
JP2016153438A (ja) * 2010-06-02 2016-08-25 アステラス ドイチュランド ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンダムスチンの経口投与形
JP2016172763A (ja) * 2010-06-02 2016-09-29 アステラス ドイチュランド ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンダムスチンの経口投与形及びその治療的使用
US10052385B2 (en) 2012-03-20 2018-08-21 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US9597397B2 (en) 2012-03-20 2017-03-21 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US9597399B2 (en) 2012-03-20 2017-03-21 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US9597398B2 (en) 2012-03-20 2017-03-21 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US9579384B2 (en) 2012-03-20 2017-02-28 Eagle Pharmaceuticals, Inc. Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
US9572888B2 (en) 2012-03-20 2017-02-21 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US9572887B2 (en) 2012-03-20 2017-02-21 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
JP2016531138A (ja) * 2013-08-27 2016-10-06 ボウドウリス バシリオス ベンダムスチンの薬学的組成物

Also Published As

Publication number Publication date
US20120157505A1 (en) 2012-06-21
CA2760085A1 (en) 2010-11-04
MX2011011109A (es) 2011-11-18
EP2424506A1 (en) 2012-03-07
WO2010126676A1 (en) 2010-11-04
CN102413816A (zh) 2012-04-11

Similar Documents

Publication Publication Date Title
JP2012525387A (ja) ベンダムスチンの経口製剤
EP2310363B1 (en) Anticancer oral formulation
EP2785691B1 (en) Donepezil pamoate, preparation method and its use
KR20190082834A (ko) 단일-투여량, 즉시-사용가능한 주사용 제제
US10543196B2 (en) Oral dosage forms of bendamustine
US20240189223A1 (en) Pharmaceutical formulations of tropomyosin related kinase (trk) inhibitors
US20200376004A1 (en) Amorphous onapristone compositions and methods of making the same
AU2011260615B2 (en) Oral dosage forms of bendamustine
US20140199382A1 (en) Stable pharmaceutical compositions of an s1p receptor agonist
US9095585B2 (en) Bioavailable compositions of amorphous piperidinyl compounds
DE602004010837T2 (de) Pharmazeutische zusammensetzung auf basis eines idazoxan-salzes oder eines seiner polymorphen
US8492423B2 (en) Pharmaceutical propylene glycol solvate compositions
US20200171031A1 (en) Pharmaceutical composition and method for preparing same
US10117939B2 (en) Pharmaceutical compositions comprising nebivolol or a nebivolol analogue
US20230293514A1 (en) Injectable depot formulation comprising cariprazine free base particles
US20120283325A1 (en) Excipient compatibility with ezatiostat
KR20230158511A (ko) 실로시빈 유사체, 염, 조성물, 및 사용 방법
WO2025165852A1 (en) Liquid formulations of lurbinectedin
KR20150001458A (ko) 용해도가 개선된 무정형의 드로네다론 염산염의 제조 방법
HK1161081A (en) Oral dosage forms of bendamustine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130326

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130326

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140415

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141125